Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

ClinicalTrials.gov ID: NCT00274313

Public ClinicalTrials.gov record NCT00274313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study of the Safety and Pharmacokinetics of 552-02 Following 14 Days of Dosing By Inhalation in Patients With Cystic Fibrosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and tolerability of a new inhaled sodium-channel blocker called 552-02 in teens and adults with cystic fibrosis. 552-02 will be inhaled once a day for 14 days using a nebulizer. A small subgroup of patients will donate blood samples for pharmacokinetic analysis to see how 552-02 is absorbed into the blood and eliminated after 14 days of treatment.

Study identification

NCT ID: NCT00274313
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Parion Sciences; Industry
Enrollment: 40 participants

Conditions and interventions

Conditions

Cystic Fibrosis

Interventions

552-02 Drug

Drug

Eligibility (public fields only)

Age range: 14 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2006 (Type not available)
Primary completion: Not listed
Completion: Aug 2006 (Type not available)
Last update posted: Jan 14, 2009

2006

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of California at San Diego	San Diego	California	92161	—
University of California at San Francisco Medical Center	San Francisco	California	94143-0359	—
The Children's Hospital	Denver	Colorado	80218	—
Nemours Children's Clinic	Orlando	Florida	32806-1101	—
University of South Florida	Tampa	Florida	33606	—
Children's Memorial Hospital	Chicago	Illinois	60614	—
University of Nebraska Medical Center	Omaha	Nebraska	68198-5190	—
Morristown Memorial Hospital	Morristown	New Jersey	07962	—
State University of New York Upstate	Syracuse	New York	13210	—
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	—
Hershey Medical Center	Hershey	Pennsylvania	17033	—
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104-4399	—
University of Pittsburgh	Pittsburgh	Pennsylvania	15213	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
University of Virginia	Charlottesville	Virginia	22908	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00274313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 14, 2009 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00274313 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →